AstraZeneca (AZN) and Merck (MRK) announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) has been approved in Japan for the treatment of adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis. This approval was by the Japanese Ministry of Health, Labor and Welfare.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Early notable gainers among liquid option names on August 23rd
- Merck’s Welireg meets Phase 3 primary endpoint in renal cell carcinoma
- Cantor Fitzgerald biotech analyst to hold an analyst/industry conference call
- PDS announces submission of Phase 3 protocol to FDA to initiate VERSATILE-003
- Merck ruling contesting IRA could drive sector rally, says Citi